AF
DSGN icon

Allworth Financial’s Design Therapeutics DSGN Stock Holding History

Allworth Financial’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39K Sell
96
-34
-26% -$424 ﹤0.01% 4629
2026
Q1 		$1.38K Buy
+130
New +$1.31K ﹤0.01% 4470
2023
Q3 		– Sell
-336
Closed -$2.12K – 3464
2023
Q2 		$2.12K Buy
336
+300
+833% +$1.84K ﹤0.01% 2461
2023
Q1 		$208 Buy
+36
New +$269 ﹤0.01% 3002

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Allworth Financial's DSGN Position: Q2 2026 in Review

Allworth Financial reduced its Design Therapeutics (DSGN) stake by 26% in Q2 2026, selling an estimated $424 and leaving 96 shares worth $1.39K. The position accounts for ﹤0.01% of the portfolio, ranked #4629.

Allworth Financial first reported a position in DSGN in Q1 2023 and has held it in 4 quarters since. The position peaked at $2.12K in Q2 2023. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Allworth Financial held 96 shares of Design Therapeutics worth $1.39K as of Q2 2026.
  • Allworth Financial sold 34 Design Therapeutics shares in Q2 2026, an estimated $424.
  • Design Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4629 holding.
  • Allworth Financial first reported a position in Design Therapeutics in Q1 2023 and has held it in 4 quarters since.
  • Allworth Financial's Design Therapeutics position peaked at $2.12K in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.